Related Experiment Video
Updated: Jun 16, 2025
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Immune responses and immunotherapeutic approaches in the treatment against cancer
1California Pacific Medical Center and Research Institute, University of California School of Medicine, San Francisco, USA. Stanley.Leong@sutterhealth.org.
Abstract:
Cancer cells within a population are heterogeneous due to genomic mutations or epigenetic changes. The immune response to cancer especially the T cell repertoire within the cancer microenvionment is important to the control and growth of cancer cells. When a cancer clone breaks through the surveillance of the immune system, it wins the battle to overcome the host's immune system. In this review, the complicated profile of the cancer microenvironment is emphasized. The molecular evidence of immune responses to cancer has been recently established. Based on these molecular mechanisms of immune interactions with cancer, clinical trials based on checkpoint inhibition therapy against CTLA-4 and/or PD-1 versus PD-L1 have been successful in the treatment of melanoma, lung cancer and other types of cancer. The diversity of the T cell repertoire is described and the tumor infiltrating lymphocytes within the cancer may be expanded ex vivo and infused back to the patient as a treatment modality for adoptive immunotherapy.
Insights
Cancer cell heterogeneity impacts immune response. This review explores the tumor microenvironment, immune interactions, and successful immunotherapies like checkpoint inhibitors and adoptive T cell transfer.
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Cancer cells exhibit heterogeneity due to genetic and epigenetic alterations.
- The tumor microenvironment and immune system, particularly T cells, play crucial roles in cancer progression and control.
- Understanding cancer immune interactions is key to developing effective therapies.
Purpose of the Study:
- To review the complex tumor microenvironment and its influence on cancer growth.
- To highlight the molecular mechanisms underlying immune responses to cancer.
- To discuss the clinical success and potential of immunotherapies.
Main Methods:
- Review of existing literature on cancer immunology and tumor microenvironment.
- Analysis of molecular evidence for immune interactions with cancer.
- Examination of clinical trial data for immunotherapies.
Main Results:
- Cancer cell heterogeneity presents challenges to immune surveillance.
- Molecular mechanisms of immune evasion and response in cancer are increasingly understood.
- Checkpoint inhibition therapies targeting CTLA-4, PD-1, and PD-L1 show significant success in various cancers.
- Tumor-infiltrating lymphocytes (TILs) offer potential for adoptive immunotherapy.
Conclusions:
- The tumor microenvironment is a critical factor in cancer development and immune evasion.
- Immunotherapies, including checkpoint inhibitors and TIL-based adoptive transfer, represent promising treatment modalities.
- Further research into cancer heterogeneity and immune interactions will drive advancements in oncology.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...